ALHC vs. MRNA: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALHC and MRNA, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
MRNA stands out with 9.92 billion USD in market value—about 3.27× ALHC’s market cap of 3.03 billion USD.
MRNA carries a higher beta at 2.00, indicating it’s more sensitive to market moves, while ALHC remains steadier at 1.33.
| Symbol | ALHC | MRNA |
|---|---|---|
| Company Name | Alignment Healthcare, Inc. | Moderna, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Healthcare Plans | Biotechnology |
| CEO | Mr. John E. Kao | Mr. Stephane Bancel |
| Price | 15.33 USD | 25.65 USD |
| Market Cap | 3.03 billion USD | 9.92 billion USD |
| Beta | 1.33 | 2.00 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | March 26, 2021 | December 7, 2018 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALHC and MRNA over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALHC and MRNA based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- Neither ALHC nor MRNA turned a profit—both carry negative P/E ratios of -32.75 and -2.95, underscoring continued losses that pressure their valuations.
- ALHC posts a negative forward PEG of -1.11, hinting at anticipated earnings decline, whereas MRNA at 0.11 has projections for stable or growing earnings.
- MRNA reports a negative Price-to-Free Cash Flow ratio of -2.47, showing a cash flow shortfall that could threaten its operational sustainability, while ALHC at 159.00 maintains positive cash flow.
| Symbol | ALHC | MRNA |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -32.75 | -2.95 |
| Forward PEG Ratio (TTM) | -1.11 | 0.11 |
| Price-to-Sales Ratio (P/S, TTM) | 1.01 | 3.14 |
| Price-to-Book Ratio (P/B, TTM) | 27.45 | 0.98 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 159.00 | -2.47 |
| EV-to-EBITDA (TTM) | -64.47 | -2.83 |
| EV-to-Sales (TTM) | 0.86 | 2.86 |
| EV-to-Free Cash Flow (TTM) | 136.01 | -2.25 |
Dividend Comparison
Neither ALHC nor MRNA currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ALHC | MRNA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALHC and MRNA, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- Both ALHC and MRNA report negative interest coverage ratios (-2.98, -207.17), meaning EBIT itself is negative—neither can cover interest, a critical solvency warning.
| Symbol | ALHC | MRNA |
|---|---|---|
| Current Ratio (TTM) | 1.69 | 4.22 |
| Quick Ratio (TTM) | 1.69 | 4.14 |
| Debt-to-Equity Ratio (TTM) | 0.07 | 0.07 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.06 |
| Interest Coverage Ratio (TTM) | -2.98 | -207.17 |